TY - JOUR AB - Unbiased high-throughput massively parallel sequencing methods have transformed the process of discovery of novel putative driver gene mutations in cancer. In chronic lymphocytic leukemia (CLL), these methods have yielded several unexpected findings, including the driver genes SF3B1, NOTCH1 and POT1. Recent analysis, utilizing down-sampling of existing datasets, has shown that the discovery process of putative drivers is far from complete across cancer. In CLL, while driver gene mutations affecting >10% of patients were efficiently discovered with previously published CLL cohorts of up to 160 samples subjected to whole exome sequencing (WES), this sample size has only 0.78 power to detect drivers affecting 5% of patients, and only 0.12 power for drivers affecting 2% of patients. These calculations emphasize the need to apply unbiased WES to larger patient cohorts. AU - Landau, Dan AU - Stewart, Chip AU - Reiter, Johannes AU - Lawrence, Michael AU - Sougnez, Carrie AU - Brown, Jennifer AU - Lopez Guillermo, Armando AU - Gabriel, Stacey AU - Lander, Eric AU - Neuberg, Donna AU - López Otín, Carlos AU - Campo, Elias AU - Getz, Gad AU - Wu, Catherine ID - 1884 IS - 21 JF - Blood TI - Novel putative driver gene mutations in chronic lymphocytic leukemia (CLL): results from a combined analysis of whole exome sequencing of 262 primary CLL aamples VL - 124 ER -